Kala-azar is not responding to primary treatment. The treatment should now consist of-
**Core Concept**
Leishmaniasis, commonly referred to as Kala-azar, is a vector-borne disease caused by the protozoan parasite Leishmania. The primary treatment for Kala-azar typically involves antimonial compounds, specifically sodium stibogluconate or meglumine antimoniate. However, in cases where the disease does not respond to primary treatment, alternative therapies must be considered to prevent disease progression and complications.
**Why the Correct Answer is Right**
In cases where Kala-azar does not respond to primary treatment with antimonials, the next step is to consider liposomal amphotericin B. Liposomal amphotericin B is a formulation of the antifungal medication amphotericin B that is encapsulated in liposomes, which allows for targeted delivery and reduced toxicity. This formulation has been shown to be effective in treating visceral leishmaniasis, including cases that are resistant to antimonials. The mechanism of action involves binding to the sterol component of the fungal cell membrane, leading to cell death. This targeted approach minimizes side effects and improves treatment outcomes.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect as it does not specify a treatment approach for Kala-azar that is not responding to primary treatment. Other options such as antimonials, miltefosine, or paromomycin may be considered, but the question is asking for the next step in treatment.
* **Option B:** This option is incorrect as it does not provide a clear treatment approach for Kala-azar that is not responding to primary treatment. While miltefosine is an alternative treatment for visceral leishmaniasis, it is not the next step in treatment when primary treatment fails.
**Clinical Pearl / High-Yield Fact**
Liposomal amphotericin B is a valuable treatment option for Kala-azar that is not responding to primary treatment. It is essential to consider the local resistance patterns and treatment guidelines when selecting an alternative treatment approach.
**Correct Answer:** C. Liposomal amphotericin B